Aflibercept in Europe: Setting New Standards in Retinal Disease Care
Strength and durability in the real world
Highlights from Bayer HealthCare’s Satellite Symposium ‘Aflibercept in Europe: Setting new standards in retinal disease care,’ held on June 7, 2015, at the European Society of Ophthalmology Congress, Vienna, Austria
This supplement is a write-up of a promotional meeting organized and funded by Bayer HealthCare. The speakers were paid honoraria toward this meeting. Bayer HealthCare checked the content for factual accuracy, to ensure it is fair and balanced, and that it complies with the ABPI Code of Practice. The views and opinions of the speakers are not necessarily those of Bayer HealthCare or the publisher. No part of this publication may be reproduced in any form without the permission of the publisher.
Articles:
Real World Data in Wet AMD: The National Aflibercept Audit
James Talks, Medical Retina Service, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Practical Benefits in Treatment Management
Sebastian Wolf, Department of Ophthalmology, Bern University Hospital, Bern, Switzerland
Treating Visual Impairment Due to DME and Macular Edema Secondary to BRVO with Aflibercept: The Highlights
Edoardo Midena, Professor of Ophthalmology and Visual Sciences at the University of Padova, School of Medicine, and Chairman of the Department of Ophthalmology, Padova University Hospital, Padova, Italy
